Profile data is unavailable for this security.
About the company
GB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company. It creates patented, disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. (GBSGB). The primary focus for the development of its lead program has been in evaluating suitable development partners that will assist it in preparing its cannabinoid-based formulas for the treatment of the motor symptoms of Parkinson's disease in human clinical trials. It is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s has a portfolio of intellectual property containing both proprietary plant-inspired formulations and its artificial intelligence-enabled drug discovery platform, and critical research contracts and key supplier arrangements. Its intellectual property covers a range of 65 medical conditions.
- Revenue in USD (TTM)0.00
- Net income in USD-1.64m
- Incorporated2018
- Employees2.00
- LocationGB Sciences Inc6450 Cameron St Ste 110ALAS VEGAS 89118-4337United StatesUSA
- Phone+1 (888) 895-3594
- Websitehttps://gbsciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Panbela Therapeutics Inc | 0.00 | -28.56m | 1.94m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
Aptevo Therapeutics Inc | 0.00 | -25.25m | 2.05m | 40.00 | -- | 0.1397 | -- | -- | -46.21 | -45.63 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -115.20 | -47.16 | -160.28 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Salarius Pharmaceuticals Inc | 0.00 | -6.46m | 2.06m | 2.00 | -- | 0.386 | -- | -- | -12.64 | -12.64 | 0.00 | 3.70 | 0.00 | -- | -- | 0.00 | -82.83 | -69.27 | -119.83 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.00 | -- | -- | -- | 60.32 | -- | -- | -- |
Dermata Therapeutics Inc | 0.00 | -9.82m | 2.07m | 8.00 | -- | 0.2862 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
Ensysce Biosciences Inc | 1.44m | -11.28m | 2.12m | 7.00 | -- | 0.844 | -- | 1.47 | -2.98 | -2.98 | 0.2845 | 0.2218 | 0.3142 | -- | 8.67 | 205,418.60 | -246.46 | -17.68 | -376.98 | -19.42 | -- | -- | -784.43 | -715.78 | -- | -5.93 | 0.235 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
ELEVAI Labs Inc | 2.47m | -4.75m | 2.21m | 18.00 | -- | 0.7164 | -- | 0.8946 | -0.2698 | -0.2698 | 0.1408 | 0.1397 | 0.7249 | 1.04 | 95.33 | 137,407.20 | -139.23 | -- | -285.65 | -- | 69.25 | -- | -192.08 | -- | 0.5439 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
GB Sciences Inc | 0.00 | -1.64m | 2.24m | 2.00 | -- | -- | -- | -- | -0.0041 | -0.0041 | 0.00 | -0.0131 | 0.00 | -- | -- | 0.00 | -597.54 | -31.80 | -- | -297.29 | -- | -- | -- | -- | -- | -6.49 | -- | -- | -- | -- | 60.24 | -- | -- | -- |
Allarity Therapeutics Inc | 0.00 | -12.82m | 2.26m | 5.00 | -- | 0.0942 | -- | -- | -2,217.58 | -2,217.58 | 0.00 | 16.98 | 0.00 | -- | -- | 0.00 | -52.54 | -- | -110.73 | -- | -- | -- | -- | -- | -- | -- | 0.0626 | -- | -- | -- | 3.02 | -- | -- | -- |
Tharimmune Inc | 0.00 | -8.88m | 2.33m | 2.00 | -- | 0.3321 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
Virpax Pharmaceuticals Inc | 0.00 | -17.23m | 2.39m | 7.00 | -- | -- | -- | -- | -13.51 | -13.51 | 0.00 | -0.9847 | 0.00 | -- | -- | 0.00 | -185.82 | -87.52 | -362.29 | -116.56 | -- | -- | -- | -- | -- | -1,596.37 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
Zyversa Therapeutics Inc | 0.00 | -21.86m | 2.41m | 7.00 | -- | 0.2266 | -- | -- | -100.63 | -100.63 | 0.00 | 10.32 | 0.00 | -- | -- | 0.00 | -84.85 | -- | -140.95 | -- | -- | -- | -- | -- | -- | -21,828.74 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Phio Pharmaceuticals Corp | 0.00 | -8.68m | 2.42m | 8.00 | -- | 0.38 | -- | -- | -23.77 | -23.77 | 0.00 | 7.40 | 0.00 | -- | -- | 0.00 | -98.62 | -71.92 | -126.86 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |